0.61
+0(+0.00%)
Currency In USD
| Previous Close | 0.61 |
| Open | 0.75 |
| Day High | 0.75 |
| Day Low | 0.61 |
| 52-Week High | 12.76 |
| 52-Week Low | 0.48 |
| Volume | 29.75M |
| Average Volume | 4.1M |
| Market Cap | 13.34M |
| PE | -0.03 |
| EPS | -17.39 |
| Moving Average 50 Days | 1.68 |
| Moving Average 200 Days | 4.38 |
| Change | 0 |
If you invested $1000 in 23andMe Holding Co. (ME) since IPO date, it would be worth $3.09 as of July 01, 2025 at a share price of $0.606. Whereas If you bought $1000 worth of 23andMe Holding Co. (ME) shares 3 years ago, it would be worth $11.66 as of July 01, 2025 at a share price of $0.606.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
GlobeNewswire Inc.
Mar 26, 2025 10:57 PM GMT
Receives Court Approval for First Day Motions to Support Ongoing Business OperationsSAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human genetics and biotechnology company,
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
GlobeNewswire Inc.
Mar 24, 2025 3:08 AM GMT
Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
GlobeNewswire Inc.
Mar 21, 2025 11:30 AM GMT
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levelsSAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics co
Data not available